Key result
Paracetamol matches ibuprofen and indomethacin for patent ductus arteriosus closure across randomized trials.
Why the study?
Treatment of PDA in neonates with NSAIDs is associated with severe side effects and contraindications, prompting comparison of paracetamol as a potentially safer alternative.
Does paracetamol improve PDA closure rates or reduce adverse events compared to ibuprofen or indomethacin in neonates with patent ductus arteriosus?
Systematic Review
Does paracetamol improve PDA closure rates or reduce adverse events compared to ibuprofen or indomethacin in neonates with patent ductus arteriosus?
Paracetamol offers similar efficacy for PDA closure as ibuprofen and indomethacin in neonates, potentially with a more favorable safety profile.
No takes yet. Share an insight, caveat, or question.
Paracetamol offers a viable alternative for neonatal PDA closure; confirms comparable efficacy to ibuprofen and indomethacin across 7 RCTs.
Yausep et al. (2019) conducted a systematic review in Patent ductus arteriosus. Paracetamol vs. Ibuprofen or indomethacin was evaluated on PDA closure rates. Paracetamol demonstrated similar efficacy to ibuprofen and indomethacin for patent ductus arteriosus closure across 7 randomized controlled trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: